|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 2018加拿大心境障碍与焦虑障碍治疗协作组/国际双相障碍学会指南:双相障碍的管理显示文摘加拿大心境障碍与焦虑障碍治疗协作组(Canadian Network for Mood and Anxiety Treatments,CANMAT)曾于2005年发布了第1版双相障碍管理指南,并分别于2007、2009和2013年对该指南进行了更新,其中最近的2次更新是与国际双相障碍学会(International Society for Bipolar Disorders,ISBD)合作完成。2018版CANMAT/ISBD双相障碍治疗指南(以下简称指南)反映了自2005年首版指南发表以来本领域取得的重大进展,包括疾病诊断与疾病管理的更新以及药物治疗与心理治疗的近期研究进展。这些前沿进展中综合考虑了循证证据的级别,并基于治疗疗效、临床实践经验、安全性、耐受性和药物导致的转相风险等,对一线、二线及三线治疗方案进行了简明而清晰的推荐。本指南中新增内容涵盖了双相Ⅰ型障碍(BD-Ⅰ)的躁狂发作急性期、抑郁发作急性期和双相障碍维持期的一线及二线治疗推荐等级划分。这种对治疗推荐等级的划分综合考虑了治疗方法对双相障碍不同时相的影响,将进一步帮助临床医生做出基于循证证据的治疗决策。锂盐、喹硫平、双丙戊酸盐、阿塞那平、阿立哌唑、帕利哌酮、利培酮和卡利拉嗪单药或联合使用被推荐为躁狂发作急性期的一线治疗选择。BD-Ⅰ抑郁期的一线治疗选择包括喹硫平、鲁拉西酮、锂盐、拉莫三嗪单药,鲁拉西酮联合锂盐或双丙戊酸盐或拉莫三嗪辅助治疗。尽管急性期治疗有效的药物通常应继续用于BD-Ⅰ的维持期治疗,但也存在一些特殊情况(例如抗抑郁药)。现有数据表明,锂盐、喹硫平、双丙戊酸盐、拉莫三嗪、阿塞那平和阿立哌唑单药或联合治疗应被视为维持治疗的初始或更换治疗方案时的一线选择。除了探讨BD-Ⅰ的相关问题外,本指南中还对双相Ⅱ型障碍(BD-Ⅱ)的临床管理进行了系统回顾并给予治疗推荐,同时针对特殊人群也有相关推荐,如处于各个生殖周期的女性、儿童、青少年和老年人。此外,本指南中还讨论了特定精神疾病及共病(如物质滥用、焦虑障碍和代谢性疾病)的影响。最后,本指南中概述了安全性和药物监测的相关问题。CANMAT/ISBD工作组希望本指南能够成为全球临床医生的实用工具。 | Lakshmi N Yatham Sidney H Kennedy Sagar V Parikh Ayal Sehaffer David J Bond Benicio N Frey Verinder Sharma Benjamin I Goldstein Soham Rej Serge Beaulieu Martin Alda Glenda MaeQueen Roumen V Milev Arun Ravindran Claire O'Donovan Diane Mclntosh Raymond W Lam Gustavo Vazquez Flavio Kapczinski Roger S Melntyre Jan Kozicky Shigenobu Kanba Beny Lafer Trisha Suppes Joseph R Calabrese Eduard Vieta Gin Malhi Robert M Post Michael Berk 胡晨(译) 王刚(译) | 2019 | 中华精神科杂志2019，52，1： | 25 |
| 2 | 每日1次利拉鲁肽与每日2次艾塞那肽治疗2型糖尿病比较:一项为期26周的随机、平行组、多国开放标记试验(LEAD-6)显示文摘背景与大多数抗高血糖药物不同,胰高血糖素样肽-1(GLP-1)受体激动剂的药理作用依赖于葡萄糖水平,并且有助于减轻患者体重。本研究比较了利拉鲁肽(一种人GLP-1类似物)与艾塞那肽(一种基于醋酸艾塞那肽的GLP-1受体激动剂)治疗2型糖尿病的疗效和安全性。方法对于用最大耐受剂量二甲双胍或(和)磺脲仍控制不良的2型糖尿病成年患者,根据之前服用的抗糖尿病药物进行分层,并随机分配这些患者额外接受利拉鲁肽1.8mg每El1次(n=233)或艾塞那肽10μg每日2次(n=231),进行为期26周的开放标记、平行组、多国(15个国家)研究。主要终点是糖化血红蛋白(HbA1c)水平的变化,疗效分析采用意向性治疗分析。本试验在Clinical Trial.gov注册,注册号为NCT00518882。结果受试者的HbA1c平均基线水平为8.2%。与艾塞那肽相比,利拉鲁肽能显著降低HbA1c平均水平[-1.12%(s=0.08%)vs-0.79%(s=0.08%);疗效差异估计值为-0.33%,95%CI-0.47%~-0.18%;P〈0.0001],并且利拉鲁肽组有更多患者HbA1c水平低于7%(54%vs543%;OR 2.02,95%CI 1.31~3.11;P=0.0015)。利拉鲁肽降低平均空腹血糖的能力也显著优于艾塞那肽[-1.61mmol/Lb=0.20)vs-0.60mmol/L(s=0.20);疗效差异估计值为-1.01mmol/L,95%CI-1.37—-0.65;P〈0.0001],但是其降低早餐和晚餐后血糖的能力较艾塞那肽差。两种药物促进患者体重减轻的作用相似(利拉鲁肽组~3.24kg vs艾塞那肽组-2.87地)。耐受性均较好,但与艾塞那肽组相比,利拉鲁肽组患者恶心的持续时间较短(估计的治疗相关事件率比值为0.448,P〈0.0001),轻度低血糖的发生率也较低(每患者每年的事件发生数为1.93vs2.60;发生率比值为0.55,95%C10.34~0.88:P=0.0131;轻度低血糖的发生率为25.5%掷33.6%)。2例同时注射艾塞那肽和一种磺脲类药物的患者发生了严重的低血糖。结论相对于艾塞那肽每日2次,利拉鲁肽每日1次能显著改善血糖控制水平,且患者的耐受性更好。研究结果提示利拉鲁肽或许是2型糖尿病的一种治疗选择,特别是在减轻体重和低血糖风险作为主要考虑因素的情况下。 | John B Buse Julia Rosenstock Giorgio Sesti Wolfgang E Schmidt Eduard Montanya Jason H Brett Marcin Zychma Lawrence Blonde 赵乐(译) | 2009 | 世界临床医学2009，，11： | 3 |
| 3 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)显示文摘 | John B Buse Julio Rosenstock Giorgio Sesti Wolfgang E Schmidt Eduard Montanya Jason H Brett Marcin Zychma Lawrence Blonde | 2009 | The Lancet2009，，9683： | 2 |
| 4 | Controlled ovarian hyperstimulation:are we monitoring the appropriate sex-steroid hormones显示文摘 | Orvieto R Eduard H Volodarsky M | 2008 | Fertility and Sterility2008，89，5： | 1 |
| 5 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)显示文摘 | John B Buse Julio Rosenstock Giorgio Sesti Wolfgang E Schmidt Eduard Montanya Jason H Brett Marcin Zychma Lawrence Blonde | 2009 | The Lancet . 2009 (9683)2009，，9683： | 1 |
| 6 | Characterization of polyploid wheat genomic diversity using a high-density 90 000 single nucleotide polymorphism array 显示文摘 | Wang SC Debbie W Kerrie F Alexandra A Shiaoman C Bevan EH Marco M Silvio S Sara GM Luigi C Anna MM Alex W Stuart S Gary B Ralf W Joerg P International Wheat Genome Sequencing Consortium Morten L Diane M Rudi A Rudy D Gina BG Abraham K Alina RA Catherine F Jerome S Michele M Curtis P Luo MC Jan DMM Jorge D Martin G Roberto T Cindy L Ivan M Colin C Keith JE Matthew H Eduard A | 2014 | Plant Biotechnol J2014，12，： | 1 |
| 7 | The ecological regulation of species diversity显示文摘 | Connell J H Eduard O | 1904 | The American Naturalist1904，，98： | 1 |
| 8 | The acquisition of tolerance toward cow's milk through probiotic supplementation:A randomized controlled trial显示文摘 | Jeroen Hol MD ab Eduard H G Van ceer | | 0，，06： | 1 |
| 9 | Retrieval effectiveness of an ontology-based model for information selection显示文摘 | Latifur K Dennis M Eduard H | 2004 | The VLDB Journal2004，13，： | 1 |
| 10 | 显示文摘 | Eduards J H | 1978 | Food Science1978，43，： | 1 |
| 11 | Characterization of Plastein Reaction Products Formed by Pepsin,α-chymotrypsin and Papain Treatment of Egg Algumin Hydrolysates显示文摘 | Eduards J H | 1978 | J Food Sci1978，，43： | 1 |
| 12 | Characterization of plastein reaction products formed by pepsin α-chymotrypsin and papain treatment of egg algum in hydrolysates显示文摘 | Eduards J H | 1978 | Journal of Food Science1978，43，： | 1 |
| 13 | Characterization of plastein peaction products formed by pepsin, α-chymotrypsin and papain treat- ment of egg algumin hydrolysates显示文摘 | Eduards T H | 1978 | J Food Sci1978，43，： | 1 |
| 14 | The Recent Evolution of Pension Funds in the Netherlands显示文摘 | Eduard H M Ponds and Bart van Riel | 2007 | The Trend to Hybrid DB-DC Plans and Beyond2007，2007，： | 1 |
| 15 | Characterization of Plastein Reaction Products Formed by Pepsin,α - chymotrypsin and Papain Treatment of Egg Algumin Hydrolysates显示文摘 | Eduards J H | 1978 | J Food Sci1978，，43： | 1 |
| 16 | Possible impacts of floods and droughts on water quality显示文摘 | Tomas H Oldrich N Eduard H | 2012 | Journal of Hydro-Environment Research2012，6，： | 1 |
| 17 | Non-destructive banana ripeness determination using a neural network-based electronic nose显示文摘 | Eduard L Evor L H Julian W G | | 0，，10： | 1 |
| 18 | Resection of complex pancreatic injuries: Benchmarking postoperative complications using the Accordion classification显示文摘AIM To benchmark severity of complications using the Accordion Severity Grading System(ASGS) in patients undergoing operation for severe pancreatic injuries. METHODS A prospective institutional database of 461 patients with pancreatic injuries treated from 1990 to 2015 was reviewed. One hundred and thirty patients with AAST grade 3, 4 or 5 pancreatic injuries underwent resection(pancreatoduodenectomy, n = 20, distal pancreatectomy, n = 110), including 30 who had an initial damage controllaparotomy(DCL) and later definitive surgery. AAST injury grades, type of pancreatic resection, need for DCL and incidence and ASGS severity of complications were assessed. Uni-and multivariate logistic regression analysis was applied. RESULTS Overall 238 complications occurred in 95(73%) patients of which 73% were ASGS grades 3-6. Nineteen patients(14.6%) died. Patients more likely to have complications after pancreatic resection were older, had a revised trauma score(RTS) < 7.8, were shocked on admission, had grade 5 injuries of the head and neck of the pancreas with associated vascular and duodenal injuries, required a DCL, received a larger blood transfusion, had a pancreatoduodenectomy(PD) and repeat laparotomies. Applying univariate logistic regression analysis, mechanism of injury, RTS < 7.8, shock on admission, DCL, increasing AAST grade and type of pancreatic resection were significant variables for complications. Multivariate logistic regression analysis however showed that only age and type of pancreatic resection(PD) were significant. CONCLUSION This ASGS-based study benchmarked postoperative morbidity after pancreatic resection for trauma. The detailed outcome analysis provided may serve as a reference for future institutional comparisons. | Jake E Krige Eduard Jonas Sandie R Thomson Urda K Kotze Mashiko Setshedi Pradeep H Navsaria Andrew J Nicol | 2017 | World Journal of Gastrointestinal Surgery2017，9，3： | 1 |
| 19 | Semi-mass culture of the dinoflagellate Gymnodinium splendens as a live food source for the initial feeding of marine finfish larvae 显示文摘 | Eduard M R Kazutsugu H | 1997 | Hydrobiologia1997，358，13： | 1 |
| 20 | 显示文摘 | Eduard Nasybuli Xu Wu Mark H Engelhard | 2013 | J Phys Chem C2013，117，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员